Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company ...
Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and ...
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
Sun Pharma is set to acquire Checkpoint Therapeutics for $355 million, enhancing its specialty portfolio with UNLOXCYT, an ...
Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for ...
5d
GlobalData on MSNSun Pharma to acquire Checkpoint TherapeuticsSun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and ...
Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This ...
The acquisition will bolster Sun Pharma’s onco-dermatology portfolio, adding Checkpoint’s recently FDA-approved cancer drug, UNLOXCYT (cosibelimab-ipdl), to its pipeline. The deal, expected to ...
FDA-approved Unloxcyt (cosibelimab-ipdl) for metastatic or locally advanced cSCC in patients unsuitable for curative treatment. The new Benzinga Rankings show you exactly how stocks stack up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results